by American College of Rheumatology Credit: CC0 Public Domain New research at ACR Convergence 2023, the American College of Rheumatology’s annual meeting, demonstrates that CAR-T cell therapy could lead to sustained suppression of autoantibodies in treatment-resistant lupus while maintaining a robust response to vaccines. Systemic lupus erythematosus (SLE, lupus) is a complex autoimmune disease marked by...
Tag: <span>Car-T cell therapy</span>
Post
Novel allogeneic CAR T cell therapy delivers promising early results in patients with metastatic clear cell renal cell carcinoma
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER ORLANDO ― The CD70-targeting allogeneic chimeric antigen receptor (CAR) T cell therapy, ALLO-316, demonstrated encouraging response rates and disease control rates in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to results of a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center and presented...
Post
To rev-up CAR T-cell therapy, inhibit the SUSD2 membrane protein, study suggests
by Ohio State University Medical Center Credit: Pixabay/CC0 Public Domain Inhibiting a particular protein in cancer-killing immune cells might improve the long-term effectiveness of CAR T-cell and other immune checkpoint therapies, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James). Published in...
Post
New biomarker for early prediction of response to CAR-T cell therapy
MEDICAL UNIVERSITY OF VIENNA A MedUni Vienna research team has discovered a highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment. The current findings are an essential step forward towards optimizing this promising therapy. The results of the study were recently published in the...
Post
Low Blood Phosphate Levels May Be Linked to Neurological Side Effects From CAR T-cell Therapy
AMERICAN ASSOCIATION FOR CANCER RESEARCH Bottom Line: Incidence and severity of neurological side effects from chimeric antigen receptor (CAR) T-cell therapy were higher in patients who had hypophosphatemia (low blood phosphate levels). Journal in Which the Study was Published: Cancer Immunology Research, a journal of the American Association for Cancer Research. Authors: Theodore Scott Nowicki, MD, PhD, assistant...
Post
CAR T-cell therapy proves effective in first trial in patients with resistant multiple myeloma
by Roswell Park Comprehensive Cancer Center Credit: CC0 Public Domain A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Roswell...
Post
Researchers shorten manufacturing time for CAR T cell therapy
by Perelman School of Medicine at the University of Pennsylvania The transducing conditions can enhance the transduction efficiency in non-activated T cells. a, Freshly isolated human T cells were either serum starved by washing and resuspending in serum-free medium or maintained in complete medium for 3–6 h. The cells were then transduced with a lentiviral vector...
Post
Study predicts who may benefit from CAR-T cell therapy for blood cancers
by Krista Conger, Stanford University Medical Center Fig. 1: IHC demonstrates CD19−/lo disease postaxi-cel and quantitative flow cytometry of LBCL preaxi-cel therapy is associated with disease progression. a Preaxi-cel H-scores did not distinguish long-term responders and those with progression postaxi-cel (P = 0.32 by t-test, P = 1 Fisher’s exact test). Waterfall plot of CD19 IHC H-scores preaxi-cel therapy (n = 44...
Post
Researchers study potential new CAR-T cell therapy for multiple myeloma
by Mayo Clinic Micrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0 Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet. “CAR-T cell therapy is a type of...
Post
A leap forward in research on CAR T cell therapy
by University of Helsinki Credit: CC0 Public Domain In cancer immunotherapy, cells in the patient’s own immune system are activated to attack cancer cells. CAR T cell therapy has been one of the most significant recent advances in immunotherapies targeted at cancer. In CAR T cell therapy, T cells are extracted from the patient for genetic modification:...
- 1
- 2